Medgenics, Inc., the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, announces the addition of two new members to its Strategic Advisory Board -Mr. Isaac Blech and Raymond Dean Hautamaki, M.D., F.A.C.P.
Mr. Blech is a renowned biotechnology industry investor, who, over the past three decades, has founded and served on the board of several companies which have produced major advances in a broad array of diseases, including the diagnosis of chlamydia, herpes, syphilis and HIV, and the treatment of cystic fibrosis, sexual dysfunction, multiple myeloma and brain cancer.
The companies he established include Celgene Corporation, ICOS Corporation, Nova Pharmaceutical Corporation, Pathogenesis Corporation, and Genetics Systems Corporation. Medgenics is looking forward to the strategic guidance of Mr Blech in finance, business development and other key aspects of its growth strategy.
Dr. Hautamaki is a practicing Board Certified Internist/Pulmonary-Critical Care Specialist in Sarasota, Florida. He is a graduate of the University of Florida College of Medicine, completing his post-graduate training at Washington University in St. Louis, Barnes-Jewish Hospitals. He is an Assistant Clinical Professor of Medicine with the Florida State University College of Medicine and is a past Chairman of Medicine and Director of Critical Care at Sarasota Memorial Hospital.
He has presented numerous abstracts at national meetings and has published over a dozen articles in peer-reviewed journals. He currently serves on the Board of Directors for Wafergen Bio-Systems in Fremont, California. Medgenics is looking forward to the contribution of Dr Hautamaki in guidance for clinical and business development, and other areas.